^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
YL201
i
Other names: YL201
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
MediLink
Drug class:
Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
Related drugs:
2d
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (clinicaltrials.gov)
P1/2, N=202, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P1/2 trial
|
cisplatin • Loqtorzi (toripalimab-tpzi) • YL201
17d
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=260, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Yidafan (ivonescimab) • YL201
2ms
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=260, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P1/2 trial
|
Yidafan (ivonescimab) • YL201
2ms
YL201-INT-101-01: A Study of YL201 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=312, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Phase classification: P1 --> P1/2 | N=196 --> 312
Phase classification • Enrollment change • First-in-human
|
Tecentriq (atezolizumab) • YL201
7ms
DeLLphi-310: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1, N=200, Recruiting, Amgen | Not yet recruiting --> Recruiting
Enrollment open
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • YL201
8ms
(DeLLphi-310): Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
P1, N=200, Not yet recruiting, Amgen
New P1 trial
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle) • YL201
9ms
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial. (PubMed, Nat Med)
YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker...Phase 3 clinical trials for patients with SCLC and NPC have already been initiated. ClinicalTrials.gov identifiers: NCT05434234 and NCT06057922 .
P1 data • Journal
|
CD276 (CD276 Molecule)
|
YL201
10ms
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
P3, N=400, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
gemcitabine • docetaxel • capecitabine • YL201
10ms
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=438, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
topotecan • YL201
10ms
A Study YL201 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=990, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | N=640 --> 990 | Trial completion date: Oct 2027 --> Oct 2028
Enrollment change • Trial completion date
|
YL201
1year
YL201-INT-101-01: A Study of YL201 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=196, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Trial completion date: Jul 2025 --> Oct 2027 | Trial primary completion date: Jul 2024 --> Apr 2027
Trial completion date • Trial primary completion date • Metastases
|
YL201
1year
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov)
P3, N=400, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
New P3 trial • Metastases
|
gemcitabine • docetaxel • capecitabine • YL201
Share via
